Assessing the ability of timolol/dorzolamide eyedrops to modulate the arterial blood flow in patients with glaucoma
- Conditions
- Therapeutic area: Diseases [C] - Eye Diseases [C11]Primary open-angle glaucoma
- Registration Number
- EUCTR2012-004946-13-BE
- Lead Sponsor
- niversity Hospitals Leuven
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients over 18 years old
Willing to give a written consent
Patient with primary-open angle glaucoma
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20
Exclusion Criteria
history of ocular trauma
intraocular surgery (except for cataract surgery)
eye disease associated with hemodynamic disturbances (except glaucoma)
systemic diseases with ocular involvement like diabetes
contra-indications to the use of topical beta-blockers or carbonic anhydrase inhibitors
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method